BR112013029385A2 - método para tratamento combinado de câncer dirigido contra egfr - Google Patents

método para tratamento combinado de câncer dirigido contra egfr

Info

Publication number
BR112013029385A2
BR112013029385A2 BR112013029385A BR112013029385A BR112013029385A2 BR 112013029385 A2 BR112013029385 A2 BR 112013029385A2 BR 112013029385 A BR112013029385 A BR 112013029385A BR 112013029385 A BR112013029385 A BR 112013029385A BR 112013029385 A2 BR112013029385 A2 BR 112013029385A2
Authority
BR
Brazil
Prior art keywords
once
directed against
combined treatment
against egfr
weeks
Prior art date
Application number
BR112013029385A
Other languages
English (en)
Inventor
Solca Flavio
Denis Louis
Shahidi Mehdi
Lorence Robert
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46085062&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112013029385(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of BR112013029385A2 publication Critical patent/BR112013029385A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

resumo patente de invenção: "método para tratamento combinado de câncer dirigido contra egfr". a presente invenção refere-se a um método de tratamento de pacientes que sofram de cânceres ativados por receptor do fator de crescimento epidérmico humano desregulado (her/egfr humano), em que um inibidor de tirosina quinase irreversível (tki) é administrado de acordo com um regime contínuo baseado em uma dose diária média na faixa de 10 a 50 mg, e o mab é coadministrado de acordo com um regime de dosagem que varia de uma dose iv semanal média de 50 a 500 mg/m2 repetida três, duas ou uma vez por semana, uma vez em duas semanas, uma vez em três semanas ou pelo menos uma vez por mês a um paciente necessitado desse tratamento.
BR112013029385A 2011-05-17 2012-05-16 método para tratamento combinado de câncer dirigido contra egfr BR112013029385A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11166446 2011-05-17
PCT/EP2012/059098 WO2012156437A1 (en) 2011-05-17 2012-05-16 Method for egfr directed combination treatment of cancer

Publications (1)

Publication Number Publication Date
BR112013029385A2 true BR112013029385A2 (pt) 2017-01-31

Family

ID=46085062

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013029385A BR112013029385A2 (pt) 2011-05-17 2012-05-16 método para tratamento combinado de câncer dirigido contra egfr

Country Status (13)

Country Link
US (4) US8828391B2 (pt)
EP (1) EP2712320B1 (pt)
JP (2) JP6228111B2 (pt)
KR (1) KR20140031903A (pt)
CN (1) CN103533961B (pt)
AU (1) AU2012257727B2 (pt)
BR (1) BR112013029385A2 (pt)
CA (1) CA2836396A1 (pt)
CL (1) CL2013003133A1 (pt)
EA (1) EA201301270A1 (pt)
IL (1) IL228741A (pt)
MX (1) MX2013013018A (pt)
WO (1) WO2012156437A1 (pt)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1948179A1 (en) 2005-11-11 2008-07-30 Boehringer Ingelheim International GmbH Quinazoline derivatives for the treatment of cancer diseases
CA2629249C (en) * 2005-11-11 2015-05-05 Boehringer Ingelheim International Gmbh Combination treatment of cancer comprising egfr/her2 inhibitors
WO2011003853A2 (en) 2009-07-06 2011-01-13 Boehringer Ingelheim International Gmbh Process for drying of bibw2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient
LT2729173T (lt) 2011-07-06 2016-10-10 Sykehuset Sorlandet Hf Egfr taikinių terapija
US9464089B2 (en) 2012-01-13 2016-10-11 Acea Biosciences Inc. Heterocyclic compounds and uses thereof
US9586965B2 (en) 2012-01-13 2017-03-07 Acea Biosciences Inc. Pyrrolo[2,3-d]pyrimidine compounds as inhibitors of protein kinases
CA2861010A1 (en) 2012-01-13 2013-07-18 Xiao Xu Heterocyclic compounds and uses as anticancer agents
US9034885B2 (en) 2012-01-13 2015-05-19 Acea Biosciences Inc. EGFR modulators and uses thereof
EP2858669A1 (en) * 2012-06-07 2015-04-15 F. Hoffmann-La Roche AG Autoimmune antibodies
BR112015013849A2 (pt) * 2012-12-21 2017-07-11 Sykehuset Soerlandet Hf terapia direcionada a egfr de distúrbios neurológicos e dor
CN105916851A (zh) 2013-07-11 2016-08-31 艾森生物科学公司 嘧啶衍生物作为激酶抑制剂
US9242965B2 (en) 2013-12-31 2016-01-26 Boehringer Ingelheim International Gmbh Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
WO2015112705A2 (en) * 2014-01-24 2015-07-30 Clovis Oncology, Inc. Therapeutic combinations for treating cancer
US9211314B2 (en) * 2014-04-04 2015-12-15 Biodesix, Inc. Treatment selection for lung cancer patients using mass spectrum of blood-based sample
CN104189920B (zh) * 2014-07-31 2017-02-01 清华大学 逆转肿瘤多药耐药的基因组合物h‑R3/PAMAM G5/MDR1 siRNA及其应用
CN104174031B (zh) * 2014-07-31 2017-06-13 清华大学 逆转肿瘤多药耐药的基因组合物‑h‑R3/PAMAM G5/GCS siRNA及其应用
EP3226869A4 (en) * 2014-12-03 2018-07-18 Auckland UniServices, Ltd. Kinase inhibitor prodrug for the treatment of cancer
US10982287B2 (en) * 2015-01-06 2021-04-20 The Johns Hopkins University Response to EGFR blockade
CN108290930A (zh) * 2015-05-01 2018-07-17 胡文聪 Pink1 c末端结构域多肽及其用于癌症治疗的方法
US20190358320A1 (en) * 2015-05-12 2019-11-28 In3Bio Ltd. Methods and compositions for inhibition of egf/egfr pathway in combination with tyrosine kinase inhibitors
US20160333087A1 (en) * 2015-05-12 2016-11-17 Bioven 3 Limited Methods and compositions for inhibition of egf/egfr pathway in combination with tyrosine kinase inhibitors
US10533011B2 (en) 2015-10-09 2020-01-14 ACEA Therapeutics, Inc. Pharmaceutical salts, physical forms, and compositions of pyrrolopyrimidine kinase inhibitors, and methods of making same
CN107684624A (zh) * 2016-08-05 2018-02-13 江苏嵌合体生物技术有限公司 表皮生长因子受体相关癌症的组合治疗
TWI808958B (zh) * 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
CN111212837A (zh) 2017-04-07 2020-05-29 艾森医药公司 吡咯并嘧啶激酶抑制剂的药用盐、物理形态和组合物及其制备方法
WO2018234556A1 (en) * 2017-06-23 2018-12-27 INSERM (Institut National de la Santé et de la Recherche Médicale) METHODS OF PREVENTING OR TREATING CANCER RESISTANCE TO EGFR INHIBITION
MA50532A (fr) * 2017-11-03 2020-09-09 Univ Virginia Patent Foundation Compositions et méthodes pour le traitement de cancers
MX2020010121A (es) * 2018-03-27 2021-01-08 Univ Texas Compuestos con actividad antitumoral contra celulas de cancer que portan las mutaciones del exon 19 del receptor 2 del factor de crecimiento epidermico humano.
KR20210024568A (ko) * 2018-06-25 2021-03-05 스펙트럼 파마슈티컬즈 인크 포지오티닙과 세포독성제 및/또는 다른 분자로 표적화된 물질의 조합 및 이의 용도
AU2019292186A1 (en) * 2018-06-25 2020-12-17 Hanmi Pharmaceutical Co., Ltd. Poziotinib combinations with an anti-HER1, HER2 or HER4 antibody and methods of use thereof
EP3599284A1 (en) 2018-07-27 2020-01-29 Bio-Id Diagnostic Inc. Simultaneous detection of multiple nucleic acid templates using modified primers
MX2021001398A (es) * 2018-08-07 2021-08-16 In3Bio Ltd Métodos y composiciones para la inhibición de la vía egf/egfr en combinación con inhibidores de la cinasa del linfoma anaplásico.
CA3133766A1 (en) * 2019-03-29 2020-10-08 Astrazeneca Ab Osimertinib for use in the treatment of non-small cell lung cancer
US20230033047A1 (en) 2020-01-11 2023-02-02 Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center Estrogen Metabolite Levels And Cancer Driver Gene Mutations In Lung Cancer Risk Stratification And Treatment
WO2022125962A1 (en) * 2020-12-11 2022-06-16 Erasca, Inc. Combination therapies for the treatment of cancer
CN112300284B (zh) * 2020-12-29 2021-04-06 慈达(广州)生物技术有限公司 核酸筛选结合抗体检测用于癌症检测中的用途及其制备的试剂盒
CN113234832B (zh) * 2021-06-30 2022-06-03 深圳市狂风生命科技有限公司 人类egfr基因错义突变分子标志物及其在预测靶向抑制剂抗药性中的应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6251912B1 (en) 1997-08-01 2001-06-26 American Cyanamid Company Substituted quinazoline derivatives
WO2000078735A1 (de) 1999-06-21 2000-12-28 Boehringer Ingelheim Pharma Kg Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
DE10063435A1 (de) 2000-12-20 2002-07-04 Boehringer Ingelheim Pharma Chinazolinderviate,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US7019012B2 (en) 2000-12-20 2006-03-28 Boehringer Ingelheim International Pharma Gmbh & Co. Kg Quinazoline derivatives and pharmaceutical compositions containing them
DE10221018A1 (de) 2002-05-11 2003-11-27 Boehringer Ingelheim Pharma Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie
US20030225079A1 (en) 2002-05-11 2003-12-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of inhibitors of the EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia (BPH)/prostatic hypertrophy
DE10307165A1 (de) 2003-02-20 2004-09-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, ihre Verwendung und Verfahren zu ihrer Herstellung
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
DE10349113A1 (de) 2003-10-17 2005-05-12 Boehringer Ingelheim Pharma Verfahren zur Herstellung von Aminocrotonylverbindungen
JP4205757B2 (ja) 2004-05-06 2009-01-07 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー ４−フェニルアミノ−キナゾリン−６−イル−アミド
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
EP1948179A1 (en) 2005-11-11 2008-07-30 Boehringer Ingelheim International GmbH Quinazoline derivatives for the treatment of cancer diseases
CA2629249C (en) 2005-11-11 2015-05-05 Boehringer Ingelheim International Gmbh Combination treatment of cancer comprising egfr/her2 inhibitors
PL1981863T3 (pl) 2006-01-26 2013-03-29 Boehringer Ingelheim Int Sposób wytwarzania pochodnych chinazoliny podstawionych przez ugrupowanie aminokrotonyloaminowe
WO2008034776A1 (en) 2006-09-18 2008-03-27 Boehringer Ingelheim International Gmbh Method for treating cancer harboring egfr mutations
CN104013956B (zh) * 2007-01-25 2018-12-18 达娜-法勃肿瘤研究所公司 抗egfr抗体在治疗egfr突变体介导的疾病中的用途
TWI377944B (en) 2007-06-05 2012-12-01 Hanmi Holdings Co Ltd Novel amide derivative for inhibiting the growth of cancer cells
EP2190878A1 (en) * 2007-09-06 2010-06-02 Genmab A/S Novel methods and antibodies for treating cancer
UY31867A (es) 2008-06-06 2010-01-29 Boehringer Ingelheim Int Nuevas formulaciones farmacéuticas sólidas que comprenden bibw 2992
EP2387401A1 (en) 2009-01-14 2011-11-23 Boehringer Ingelheim International GmbH Method for treating colorectal cancer
WO2010085845A1 (en) 2009-01-28 2010-08-05 The University Of Queensland Cancer therapy and/or diagnosis
CA2760794C (en) * 2009-05-05 2017-07-25 Dana Farber Cancer Institute Egfr inhibitors and methods of treating disorders
WO2011003853A2 (en) 2009-07-06 2011-01-13 Boehringer Ingelheim International Gmbh Process for drying of bibw2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient
JP5956342B2 (ja) * 2009-11-03 2016-07-27 シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ 形質導入Ｔ細胞選択のためのトランケート上皮増殖因子レセプタ（ＥＧＦＲｔ）
EP2509592A1 (en) 2009-12-07 2012-10-17 Boehringer Ingelheim International GmbH Bibw 2992 for use in the treatment of triple negative breast cancer
KR101217526B1 (ko) 2010-06-11 2013-01-02 한미사이언스 주식회사 아마이드 유도체 또는 이의 약학적으로 허용 가능한 염을 포함하는 약제학적 조성물
CA2832817A1 (en) * 2011-04-11 2012-10-18 Abbvie Inc. Parp inhibitors for the treatment of cipn

Also Published As

Publication number Publication date
JP2016065109A (ja) 2016-04-28
CN103533961B (zh) 2016-08-03
CA2836396A1 (en) 2012-11-22
US20120294867A1 (en) 2012-11-22
JP2014513706A (ja) 2014-06-05
AU2012257727A1 (en) 2013-10-24
EP2712320A1 (en) 2014-04-02
JP6282296B2 (ja) 2018-02-21
US20160101175A1 (en) 2016-04-14
IL228741A (en) 2016-08-31
KR20140031903A (ko) 2014-03-13
EP2712320B1 (en) 2019-10-02
CL2013003133A1 (es) 2014-07-11
US20170312360A1 (en) 2017-11-02
AU2012257727B2 (en) 2016-09-01
US20140341926A1 (en) 2014-11-20
JP6228111B2 (ja) 2017-11-08
US8828391B2 (en) 2014-09-09
WO2012156437A1 (en) 2012-11-22
IL228741A0 (en) 2013-12-31
NZ616183A (en) 2015-09-25
EA201301270A1 (ru) 2014-05-30
MX2013013018A (es) 2014-01-31
CN103533961A (zh) 2014-01-22

Similar Documents

Publication Publication Date Title
BR112013029385A2 (pt) método para tratamento combinado de câncer dirigido contra egfr
Penprase et al. The efficacy of preemptive analgesia for postoperative pain control: a systematic review of the literature
BR112021002145A2 (pt) Métodos e composições para inibição da via egf/egfr em combinação com inibidores da quinase de linfoma anaplásico
MX2014000130A (es) Procedimientos y composiciones para la inhibicion de resorcion osea.
PH12015502691A1 (en) Use of high dose pridopidine for treating huntington's disease
GB2487712A8 (en) use of the phtocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
MX2020009773A (es) Terapia de combinacion.
MX2007004549A (es) Tratamiento combinado con bortezomib y un inhibidor de cinasa del receptor del factor de crecimiento epidermico.
NZ703940A (en) Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
NZ736048A (en) The use of inhibitors of bruton’s tyrosine kinase (btk)
BR112014004370A2 (pt) métodos para tratar distúrbios cardiovasculares
EA201491460A1 (ru) ПРИМЕНЕНИЕ ЛАХИНИМОДА В ЛЕЧЕНИИ ПАЦИЕНТОВ С БОЛЕЗНЬЮ КРОНА, У КОТОРЫХ НЕ ЭФФЕКТИВНА ТЕРАПИЯ ПЕРВОЙ ЛИНИИ АНТИ-TNFα
MX2021011110A (es) Tratamiento de ataque de angioedema hereditario con dosis reducida de anticuerpos que se unen a calicreína plasmática humana.
NZ756264A (en) Treatment of brain cancer
BR112013000190A2 (pt) formas de dosagem de retenção gástrica compreendendo um análogo de gaba e um opioide
BR112014013924A8 (pt) métodos para tratar distúrbios cardiovasculares
NZ700924A (en) Dosage regimen for a pi-3 kinase inhibitor
NZ598171A (en) Methods and compositions for treating thyroid-related medical conditions with reduced folates
BR112018068784A2 (pt) método para o tratamento de leucemia
MX2015009546A (es) Dosificacion aumentada de efavirenz para el tratamiento de cancer.
PH12020500096A1 (en) Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a raf inhibitor
TW200608959A (en) Treatment with oxaliplatin and an egfr-inhibitor
BR112014009141A2 (pt) regime de dosagem para um modulador ou agonista do receptor s1p
BR112017024073A2 (pt) métodos e composições para a inibição da via egf/egfr em combinação com inibidores de tirosina quinase
BR112015012497A2 (pt) combinações farmacêuticas

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]